Updates on First-line and Subsequent Treatment Options for Advanced Endometrial Cancer

Vicky Makker, MD and Ramez Eskander, MD discuss the increasing global incidence of endometrial cancer.

Experts discuss how molecular testing can inform treatment selection and patient management for those with endometrial cancer.

A comprehensive overview of first-line treatment options for patients with advanced endometrial cancer.

Vicky Makker, MD, leads a discussion of efficacy data from the KEYNOTE-775 trial on combination lenvatinib/pembrolizumab in patients with endometrial cancer.

A brief review of treatment interruption, discontinuation, and dose modification rates in patients receiving combination lenvatinib/pembrolizumab in the KEYNOTE-775 trial or in the experts’ clinical practice.

Shared insight on the management of commonly observed adverse events in patients with endometrial cancer who are receiving combination lenvatinib/pembrolizumab.

Experts highlight key ongoing trials and emerging therapies for patients with endometrial cancer.